JPMorgan raises target for AbbVie stock from USD 285 to USD 300

Published on 10/09/2026 at 15:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan keeps AbbVie at Overweight on October 8, 2026. AbbVie stock costs EUR 243.15 on October 9, 2026 after EUR 242.85, plus 0.12 percent.

Key points in brief

JPMorgan lifted AbbVie price target from USD 285.00 to USD 300.00 on October 8, 2026.
Second-quarter 2026 revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock was trading at EUR 243.15 at Lang & Schwarz on October 9, 2026, plus 0.12 percent versus EUR 242.85.

Bauhaus-Designposter mit BIOPHARMA-Schriftzug und geometrischen Molekülformen in Primärfarben — AbbVie Inc. US00287Y1091 Bauhaus Poster BIOPHARMA Geometrie Primärfarben Kreise Dreiecke molekulare Pharma Strukturen, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 243.15 at Lang & Schwarz on October 9, 2026, up 0.12 percent versus its prior close. On October 8, 2026, JPMorgan raised its AbbVie price target from USD 285.00 to USD 300.00 and maintained an Overweight rating, as Markets Insider reported. The target increase of 5.26 percent puts the analyst debate on AbbVie's pipeline alongside its established immunology portfolio.

Three recent AbbVie events

On October 5, 2026, AbbVie and Genmab reported Phase 3 results showing a 51.00 percent reduction in the risk of disease progression or death for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma, according to MarketBeat. On October 7, 2026, AbbVie received two FDA Breakthrough Therapy Designations for Temab-A, covering colorectal cancer and non-small cell lung cancer, the same MarketBeat report noted. On October 8, JPMorgan set the new USD 300.00 target after its USD 285.00 level.

What does the target change mean?

The 5.26 percent target increase is a quantified signal that the pipeline is becoming more important to the AbbVie investment case. JPMorgan cited Skyrizi, Rinvoq and the neuroscience portfolio in its outlook, while Cantor Fitzgerald set a USD 290.00 target after USD 285.00 on October 8, 2026, according to Investing.com. The counterweight is commercial execution: the report said Skyrizi and Rinvoq prescription data were tracking below consensus estimates.

Revenue and earnings context

AbbVie reported USD 16.99 billion of revenue in the second quarter of 2026, up 10.20 percent from the same quarter a year earlier, while earnings per share reached USD 3.65 versus a USD 3.61 consensus estimate, according to MarketBeat. The next quantified checkpoint is scheduled for October 30, 2026, when AbbVie plans to announce third-quarter 2026 results before the market opens, according to StockTitan.

AbbVie stock holds near its yearly high

At Lang & Schwarz, AbbVie stock was trading at EUR 243.15 on October 9, 2026 at 3:01 p.m. CEST, plus 0.12 percent versus the EUR 242.85 prior close dated October 8, 2026. The primary listing is on the NYSE, where the 52-week range was USD 190.75 to USD 274.94 and market capitalization was USD 481.3 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.